Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07071688
Starting soon Observational

Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy

NCT07071688 · tracked via the Priya Life Science China tracker
Sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Started
2025-07-20
Last updated
2025-07-17

Condition(s) studied

TumorRadiotherapyBiomarker

Study summary

Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significantly elevated in patients with radioresistant tumors and may serve as a predictive biomarker for radiotherapy sensitivity. This study aims to conduct a multicenter, bidirectional cohort study to systematically evaluate the predictive value of peripheral blood CHI3L1 as a pan-cancer biomarker for tumor response to radiotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Voluntarily signed informed consent form; * Age ≥ 18 years; * No restrictions on sex; * Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Exclusion Criteria: * Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose \> 1.5 × ULN), or psychiatric disorders. * Deemed unsuitable for participation in the study at the discretion of the investigators.

Primary outcome measure(s)

  • Objective Response Rate（ORR） — Through study completion, up to 3 years
    Objective Response Rate (ORR) after Radiotherapy in Tumor Patients

Trial sites (3)

FacilityCityRegionStatus
Nanfang hospital, Southern medical university, Guangzhou, Guangdong 510515 Guangzhou Guangzhou
Huizhou Central People's Hospital, Huizhou Huizhou China
Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou, Meizhou, Meizhou China

More Nanfang Hospital, Southern Medical University trials in China

Immune Dynamics in the Natural History of Chronic HBV Infection Recruiting
Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery Patients Recruiting
Correlation and Predictive Research of Metal Elements in Radiation-Induced Oral Mucositis Recruiting
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study Recruiting
Large Language Model-Based Emotional Management for Breast Cancer Patients Active, not recruiting

Other trials for the same condition

Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors Enrolling by invitation
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study Recruiting
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy Starting soon
Dietary Supplements to Treat Radiation-Induced Rectal Injury Recruiting
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07071688 on ClinicalTrials.gov ↗ ← All trials in China